Tristel Regulatory News (TSTL)

10 June 2014

Tristel plc

("Tristel" or "the Company")

Trading Update

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, provides a trading update for the year ending 30 June 2014, ahead of previously upgraded expectations announced in April.

Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.

Tristel announced in both March and April that it was experiencing strong momentum in its underlying business. This trend is expected to continue through to its June year end and beyond. 

The Company now anticipates further acceleration in revenue growth and as a consequence has raised its internal expectations both for the current and subsequent financial years. Pre-tax profit (before share-based payments) for the year ending 30 June 2014 is now expected to be not less than £1.75m (2013: £0.48m adjusted pre-tax profit*).

Paul Swinney, Chief Executive, comments "We are experiencing a rise in sales in all three portfolios and across most geographical markets. The pace of growth is higher than previously anticipated and with margins also improving and costs stable, the impact on the bottom line is both significant and immediate.

"We can conclude that the re-shaping of our business over the past three years has been firmly cemented in place. The growing revenue contributions from the new products and new markets we have invested in have become both visible and predictable, and with an exciting pipeline of new innovations built upon our proprietary chlorine dioxide technology, we view the future with increasing confidence."

*Adjusted for non-recurring items of £2.2m

For further information please contact: